Michael Woloschak

1.0k total citations
23 papers, 848 citations indexed

About

Michael Woloschak is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Michael Woloschak has authored 23 papers receiving a total of 848 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Endocrinology, Diabetes and Metabolism, 7 papers in Molecular Biology and 4 papers in Surgery. Recurrent topics in Michael Woloschak's work include Pituitary Gland Disorders and Treatments (5 papers), Diabetes Treatment and Management (5 papers) and Glioma Diagnosis and Treatment (4 papers). Michael Woloschak is often cited by papers focused on Pituitary Gland Disorders and Treatments (5 papers), Diabetes Treatment and Management (5 papers) and Glioma Diagnosis and Treatment (4 papers). Michael Woloschak collaborates with scholars based in United States, Switzerland and Germany. Michael Woloschak's co-authors include Kalmon D. Post, Charles T. Roberts, Derek LeRoith, Z. Shen‐Orr, Martin L. Adamo, Hauke Werner, Jiaqi Xiao, James L. Roberts, R. Balena and David Wolfe and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Clinical Endocrinology & Metabolism and Cancer.

In The Last Decade

Michael Woloschak

23 papers receiving 835 citations

Peers

Michael Woloschak
J Zapf Switzerland
Song-Guang Ren United States
John Apps United Kingdom
Dalia L. Batista United States
Michael Woloschak
Citations per year, relative to Michael Woloschak Michael Woloschak (= 1×) peers Kam‐Tsun Tang

Countries citing papers authored by Michael Woloschak

Since Specialization
Citations

This map shows the geographic impact of Michael Woloschak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Woloschak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Woloschak more than expected).

Fields of papers citing papers by Michael Woloschak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Woloschak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Woloschak. The network helps show where Michael Woloschak may publish in the future.

Co-authorship network of co-authors of Michael Woloschak

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Woloschak. A scholar is included among the top collaborators of Michael Woloschak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Woloschak. Michael Woloschak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Broomfield, Alexander, James Davison, Maria Alice Donati, et al.. (2022). Baby-COMET methodology: A clinical study of the efficacy, safety, pharmacokinetics, and pharmacodynamics of avalglucosidase alfa in treatment-naïve participants with IOPD. Molecular Genetics and Metabolism. 135(2). S26–S26. 1 indexed citations
2.
Coles, Theresa, Adrian F. Hernandez, Bryce B. Reeve, et al.. (2021). Enabling patient-reported outcome measures in clinical trials, exemplified by cardiovascular trials. Health and Quality of Life Outcomes. 19(1). 164–164. 10 indexed citations
3.
Davies, Melanie J., Steve Baín, G. Charpentier, et al.. (2019). A Randomized Controlled, Treat-to-Target Study Evaluating the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) Administered Using Either Device-Supported or Routine Titration in People With Type 2 Diabetes. Journal of Diabetes Science and Technology. 13(5). 881–889. 23 indexed citations
4.
Henry, Robert R., et al.. (2012). Efficacy and Safety of Taspoglutide in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Plus Pioglitazone over 24 Weeks: T-Emerge 3 Trial. The Journal of Clinical Endocrinology & Metabolism. 97(7). 2370–2379. 23 indexed citations
5.
Bergenstal, Richard M., Adriana Costa e Forti, Jean‐Louis Chiasson, et al.. (2012). Efficacy and Safety of Taspoglutide Versus Sitagliptin for Type 2 Diabetes Mellitus (T-Emerge 4 Trial). Diabetes Therapy. 3(1). 13–13. 43 indexed citations
6.
Eisenberg, Mark, Michael Woloschak, Chandranath Sen, & David Wolfe. (1997). Loss of heterozygosity in the retinoblastoma tumor suppressor gene in skull base chordomas and chondrosarcomas. Surgical Neurology. 47(2). 156–160. 34 indexed citations
7.
Woloschak, Michael, et al.. (1997). Frequent inactivation of thep16 gene in human pituitary tumors by gene methylation. Molecular Carcinogenesis. 19(4). 221–224. 77 indexed citations
8.
Woloschak, Michael, et al.. (1996). Abundance and state of phosphorylation of the retinoblastoma gene product in human pituitary tumors. International Journal of Cancer. 67(1). 16–19. 38 indexed citations
9.
Woloschak, Michael, et al.. (1996). Molecular and cellular responses to DNA damage in a murine pituitary adenoma cell line. Molecular and Cellular Endocrinology. 119(1). 61–68. 11 indexed citations
10.
Woloschak, Michael & Joseph L. Roberts. (1995). Characterization and Regulation of Upstream Transcripts of the Murine Proopiomelanocortin Gene. Biochemical and Biophysical Research Communications. 210(2). 281–287. 1 indexed citations
11.
Woloschak, Michael, et al.. (1995). Detection of polyomaviral DNA sequences in normal and adenomatous human pituitary tissues using the polymerase chain reaction. Cancer. 76(3). 490–496. 25 indexed citations
12.
Woloschak, Michael, James L. Roberts, & Kalmon D. Post. (1994). Loss of heterozygosity at the retinoblastoma locus in human pituitary tumors. Cancer. 74(2). 693–696. 44 indexed citations
13.
Woloschak, Michael, Kalmon D. Post, & James L. Roberts. (1994). Effects of antisense DNA on POMC mRNA and ACTH levels in cultured human corticotroph adenoma cells. Journal of Endocrinological Investigation. 17(10). 817–819. 1 indexed citations
14.
Woloschak, Michael, James L. Roberts, & Kalmon D. Post. (1994). c-myc, c-fos, and c-myb gene expression in human pituitary adenomas.. The Journal of Clinical Endocrinology & Metabolism. 79(1). 253–257. 38 indexed citations
15.
Woloschak, Michael. (1994). c-myc, c-fos, and c-myb gene expression in human pituitary adenomas. The Journal of Clinical Endocrinology & Metabolism. 79(1). 253–257. 13 indexed citations
16.
Woloschak, Michael, Z. Shen‐Orr, Derek LeRoith, & Charles T. Roberts. (1993). Nutritional Regulation of Insulin-Sensitive Glucose Transporter Gene Expression in Rat Cardiac Muscle. Experimental Biology and Medicine. 203(2). 172–174. 6 indexed citations
17.
Foyt, Howard L., F Lanau, Michael Woloschak, Derek LeRoith, & Charles T. Roberts. (1992). Effect of growth hormone on levels of differentially processed insulin-like growth factor I mRNAs in total and polysomal mRNA populations.. Molecular Endocrinology. 6(11). 1881–1888. 34 indexed citations
18.
Jansson, J.-O., Lena Carlsson, S. Ekberg, et al.. (1990). Pulsatile Growth Hormone Secretory Pattern: Autofeedback Regulation and Effects on Growth Factors. Acta Paediatrica. 79(s367). 98–102. 3 indexed citations
19.
Werner, Hauke, Michael Woloschak, Martin L. Adamo, et al.. (1989). Developmental regulation of the rat insulin-like growth factor I receptor gene.. Proceedings of the National Academy of Sciences. 86(19). 7451–7455. 292 indexed citations
20.
Thibonnier, Marc & Michael Woloschak. (1988). Platelet Aggregation and Vasopressin Receptors in Patients with Diabetes Mellitus. Experimental Biology and Medicine. 188(2). 149–152. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026